ABSTRACT The neuropeptides substance P and neurokinin A are present in sensory airway nerves. Their effect on airway calibre was compared in six healthy non-smoking subjects and six asthmatic subjects. On separate days increasing concentrations (from 10-9 to 10'6 mol/ml) of each neuropeptide were administered by nebuliser and the airway response measured as change in specific airway conductance (sGaw). Substance P and neurokinin A caused no change in sGaw in the healthy subjects. Inhalation of substance P up to the highest concentration of 106 mol/ml caused no change in sGaw in the asthmatic subjects. Neurokinin A, however, caused bronchoconstriction with a mean fall in sGaw of 48% (SEM 12%) after 5 x 10-mol/ml. leading to smooth muscle contraction, mucus secretion, vasodilatation, and protein extravasation (axon reflex hypothesis). Substance P, however, when inhaled has only a weak bronchoconstrictor effect. " In animals and in isolated human airways, neurokinin A is a more potent bronchoconstrictor than substance p. ' -1 We decided to compare the effect of inhaling substance P and neurokinin A on airway calibre of normal and mildly asthmatic subjects.
Several neuropeptides have been detected in the airway by immunological techniques.' These include substance P and neurokinin A, two members of the tachykinin peptide family. These structurally related peptides are potent smooth muscle constrictors and blood vessel dilators. 2 Substance P has been localised within sensory airway nerves of animals and man: nerve fibres with substance P like immunoreactivity have been seen in the airway mucosa; around blood vessels, submucosal glands, and tracheobronchial ganglion cells; and within airway smooth muscle. 34 Neurokinin A is a recently discovered mammalian tachykinin, whose structure is contained, with substance P, in one of the two mammalian tachykinin precursors, ,B preprotachykinin.5 Neurokinin A coexists with substance P within peripheral sensory nerves,6 and its presence within sensory airway nerves was reported recently.7 8 A potential role for tachykinins in asthma has been suggested recently.9 1o From experiments in rodents it was hypothesised that mechanical and chemical stimulation of sensory airway nerve endings cause antidromic release of substance P, neurokinin A and calcitonin gene related peptide from axon collaterals, leading to smooth muscle contraction, mucus secretion, vasodilatation, and protein extravasation (axon reflex hypothesis). Substance P, however, when inhaled has only a weak bronchoconstrictor effect. " In animals and in isolated human airways, neurokinin A is a more potent bronchoconstrictor than substance p. ' -1 We decided to compare the effect of inhaling substance P and neurokinin A on airway calibre of normal and mildly asthmatic subjects.
Methods

PATIENTS
The study population consisted of six healthy, nonsmoking volunteers and six patients with a history of mild asthma. The normal volunteers, two men and four women, aged 24-35 years, had normal lung function (mean FEV1 115% of predicted, mean sGaw 1-92 (0-04) s'-kPa-'). The asthmatic patients, four men and two women, aged 18-28 years, had only minor symptoms during the weeks preceding the trial. Their clinical characteristics are given in table 1. Five of the six asthmatic subjects had positive skinprick test responses, five to house dust mite and two to grass pollen. Their FEV1 was greater than 70% predicted (mean 80 (SEM 3)) and their PC20 (provocative concentration causing a 20% fall in FEV1) methacholine less than 8 mg/ml. PC20 methacholine was determined by measuring the FEV, decrease after inhalation of doubling concentrations of methacholine, according All subjects gave informed consent. The study design was approved by the ethical committee of the University Hospital of Ghent.
MATERIALS AND SOLUTIONS
Substance P was obtained from UCB Bioproducts (Brussels, Belgium), neurokinin A from Peninsula (St Helens, England), and human serum albumin from Behringwerke AG (Marburg, Germany).
The neuropeptides were dissolved in saline containing 1% human serum albumin. Saline containing 1% human serum albumin served as a control solution (pH 8-0, temperature 4°C, osmolality 320 mmol/kg).
The neuropeptides were diluted freshly each day and kept on ice.
BRONCHIAL CHALLENGE Subjects underwent a bronchial challenge with substance P, neurokinin A and a control solution in a randomised order on three separate days. Solutions were nebulised with a Wiesbadener-Doppel inhalator (Wiesbadener Inhalatoren-Vertrieb, Wiesbaden, Germany) with an airflow of 6 1 min'-. Increasing concentrations of substance P or neurokinin A were inhaled(O1-9,5 x 10-9, 10-8,5 x 10-8, 10-7,5 x 10-7, and 10-6 mol/mI) at 15 minute intervals. Control solutions were administered in the same manner.
The nebulised solutions were inhaled during two minutes of tidal breathing with the outlet of the nebuliser in the mouth and the nose closed by a clip. Under these conditions 02 ml of the solution leaves the nebuliser. The three challenges were performed at an interval of at least one week. All medications taken by the asthmatic patients (sympathomimetics and theophylline) were stopped 24 hours before each challenge. The challenge tests were started at 2 pm.
LUNG FUNCTION MEASUREMENTS
The FEV1 was measured with a water sealed spirometer (Expirograph, Godart) as the highest of three consecutive measurements. Specific airway conductance (sGaw) was calculated from airway resistance and thoracic gas volume measured with a constant volume body plethysmograph (Jaeger, Wurzburg, Germany). Measurements were made with the subjects breathing quietly under BTPS conditions, inhaling warmed, humidified air from a separate rebreathing' bag to minimise temperature and humidity artefacts. 6 Each value represents the mean of eight consecutive measurements. sGaw was measured before the start of the challenge and 5 and 15 minutes after the start of inhalation for each concentration. When sGaw had decreased by more than 35% it was measured every 15 minutes until it had returned to normal values.
STATISTICAL ANALYSIS
The results are expressed as the percentage change in specific airway conductance (A % sGaw), and reported as the means with standard errors in parentheses. The data from the two groups of subjects, the three solutions, and the different concentrations were compared by three way analysis of variance. Paired data were compared by the Wilcoxon's matched pairs signed rank test. A p value of < 0 05 was regarded as significant.
Results
Inhalation of substance P and neurokinin A by the healthy, non-smoking subjects did not cause a significant change in sGaw (fig 1) 23 On the SP-P (P for physalaemin) subtype, SP, physalaemin, eledoisin, and kassinin are more or less equipotent, while kassinin and eledoisin are much more active than substance P on the SP-E (E for eledoisin) receptor. Recently two new mammalian tachykinins, neurokinin A (= substance K) and neurokinin B (= neuromedin K) were discovered.5 24 Recent data have shown that these two new tachykinins are more potent on the SP-E than on the SP-P receptor subtype.25 On the basis of animal studies'2-14 and findings from isolated human airways'9 20 a predominance of bronchial SP-E receptors has been postulated. Our results for human airways in vivo are compatible with this view, as neurokinin A was definitely more potent than substance P. The mode of action of tachykinins in human airways is not known. In addition to bronchial smooth muscle contraction, substance P causes bronchial microvascular leakiness,26 airway mucus secretion,27 and histamine release from mast cells.28 Experiments in rabbits and rats show that a considerable portion of the bronchoconstrictor effect of tachykinins arises from an interaction with cholinergic nerves, probably through release of acetylcholine from cholinergic nerve endings.'4 29 Studies on isolated human bronchi suggested that substance P has a direct smooth muscle contracting effect, as substance P induced contraction is resistant to pretreatment with a histamine and muscarinic receptor antagonist. '7 This observation cannot, however, be extended to human bronchi in vivo as nerve mediated responses are often lost during in vitro studies. 30 31 Inhalation of capsaicin, a neurotoxin that damages sensory nerve fibres causing release of substance P, caused bronchoconstriction in man. 32 The bronchoconstriction has a rapid onset (under 20 seconds) and short duration (under 60 seconds), and was found to be largely inhibited by the anticholinergic agent ipratropium bromide. It is, however, questionable whether the bronchoconstriction was due to release of substance P or another tachykinin: capsaicin has been shown to cause reflex bronchoconstriction in dogs33 and the time course of capsaicin induced bronchoconstriction was very different from the time course that we observed after inhalation of neurokinin A by asthmatic patients.
In conclusion, our study shows that tachykinins are able to cause bronchoconstriction in asthmatic subjects. As in animal and isolated human airways, neuJoos, Pauwels, van der Straeten rokinin A is a more potent bronchoconstrictor than substance P, suggesting a predominance of SP-E receptor sites in human airways. Axon reflexes could therefore play a part in the pathogenesis of asthma. The natural stimuli that cause tachykinin release from sensory airway nerve endings are unknown at the present. Further studies are necessary to define the exact role and the mode of action of tachykinins in human airways.
